Abiopharma

🔍 Aziz Kabeer (Executive)

Company: AN2 Therapeutics, Inc. (ANTX)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Acquired 11,560 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: A | equity_swap_involved: false | shares_owned_after: 52,479.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,995,958.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-12 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 377,542.00 | Footnotes: F3

Footnotes:

• F1: Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.
• F2: Shares are held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
• F3: Shares are held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.